In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

TD Cowen analyst Joseph Thome maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises t

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in t

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weigh

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform

Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweigh

Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform an

Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raise

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) wi

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

Axsome (AXSM) Q1: Revenue beats, but wider loss and rising expenses weigh on shares. Get the key dat

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) wi

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.26) per share which missed the an

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding it

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for a

UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin

Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturi

PPL Corporation (NYSE:PPL) announced it plans to sell 20,000,000 equity units in a public offering.

William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-51

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. l

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent ge

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss a

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe